Microfluidic sample preparation for genomic sequencing of clinical pathogen isolates

 描述(由申请人提供)：DNA测序的成本近年来大幅下降，而样品制备成本相对持平。其结果是，今天显而易见的“样品准备瓶颈”将在几年内影响到基本上所有的测序研究。此外，标准方法的样本量要求排除了重要的低产量临床样本类型。R21项目的目标是验证和展示一种用于病原体基因组测序的实用集成微流控样品制备技术，该技术能够显著提高样品制备成本、周转时间和低投入能力。将整个样品制备过程集成到单个微型设备中，将通过降低试剂消耗、对其他消耗品的需求、资本设备成本、实际操作时间和程序错误，将高通量样品制备的实际成本降低10倍以上。我们将在正在进行的临床试验Project Clear的金黄色葡萄球菌样本上验证这项技术，然后继续对大量额外的Project Clear样本进行测序。

 DESCRIPTION (provided by applicant): DNA sequencing has seen dramatic cost reductions in recent years, while sample preparation costs have been relatively flat. The result is a `sample preparation bottleneck' apparent today will affect essentially all sequencing studies within a few years. In addition, sample input quantity requirements for standard approaches exclude important low-yield clinical sample types. The goal of this R21 project is to validate and demonstrate a practical integrated microfluidic sample preparation technology for pathogen genome sequencing that enables a significant advance in sample preparation cost, turn-around-time, and low-input capability. Integration of the entire sample preparation process in a single micro device will reduce real-world cost for high-throughput sample preparation more than 10-fold by lowering reagent consumption, the need for other consumables, capital equipment costs, hands-on time, and procedural errors. We will validate this technology on S. Aureus samples from an ongoing clinical trial, Project CLEAR, and then go on to sequence a large number of additional Project CLEAR samples.